AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE
NEW YORK and LONDON, October 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Akari clinical data from 38 subjects (in previous clinical studies and healthy volunteers) support robust PK/PD model simulations used to select doses for …
[Read more...] about Rich Database Underpins Predictive PK/PD Model
Akari's robust PK/PD model simulated 10,000 virtual patients informing U.S. FDA MIDD interactions that helped confirm PK/PD model suitability & doses …
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing …
NEW YORK and LONDON, September 22, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
